Notice of Proposed Sale · 144
Harmony Biosciences Holdings, Inc.
HRMYNASDAQEQUITYCurrent
Notice of Proposed Sale
Structured filing — 144
primary_doc.xml
Notice of proposed sale. The proposed amounts below do not establish that a sale occurred.
Proposed-sale notice
- Issuer
- HARMONY BIOSCIENCES HOLDINGS, INC.
- Issuer CIK
- 0001802665
- SEC file number
- 001-39450
- Phone
- (484) 539-9800
- Person for whose account securities are to be sold
- VALOR IV PHARMA HOLDINGS LLC
- Relationships to issuer
- Director
- Street
- 630 W GERMANTOWN PIKE
- Street (continued)
- SUITE 215
- City
- PLYMOUTH MEETING
- State / country code
- PA
- Postal code
- 19462
Securities proposed for sale
| Security | Proposed units | Aggregate market value | Units outstanding | Approximate sale date | Exchange | Broker / market maker |
|---|---|---|---|---|---|---|
| Common | 700,883 | 26,563,465.70 | 58,236,393 | 08/07/2026 | NASDAQ | Morgan Stanley Smith Barney LLC Executive Financial Services |
Broker / market maker — proposed row 1, entry 1
- Name
- Morgan Stanley Smith Barney LLC Executive Financial Services
- Street
- 1 New York Plaza
- Street (continued)
- 8th Floor
- City
- New York
- State / country code
- NY
- Postal code
- 10004
Acquisition of securities to be sold
| Security | Acquired | Nature of acquisition | Acquired from | Amount acquired | Gift transaction | Payment date | Nature of payment |
|---|---|---|---|---|---|---|---|
| Common | 10/06/2017 | Private Acquisition from Issuer/Affiliate | Issuer | 700,883 | N | 10/06/2017 | Cash |
Sales reported in the preceding three months
| Seller | Security | Sale date | Amount sold | Gross proceeds |
|---|---|---|---|---|
| VALOR IV PHARMA HOLDINGS LLC | Common | 08/05/2026 | 55,847 | 2,104,873.00 |
| VALOR IV PHARMA HOLDINGS LLC | Common | 08/05/2026 | 45,642 | 1,727,093.00 |
| VALOR IV PHARMA HOLDINGS LLC | Common | 06/22/2026 | 15,001 | 500,583.00 |
Seller — prior-sale row 1, entry 1
- Name
- VALOR IV PHARMA HOLDINGS LLC
- Street
- 630 W. Germantown Pike, Suite 215
- City
- Plymouth Meeting
- State / country code
- PA
- Postal code
- 19462
Seller — prior-sale row 2, entry 1
- Name
- VALOR IV PHARMA HOLDINGS LLC
- Street
- 630 W. Germantown Pike, Suite 215
- City
- Plymouth Meeting
- State / country code
- PA
- Postal code
- 19462
Seller — prior-sale row 3, entry 1
- Name
- VALOR IV PHARMA HOLDINGS LLC
- Street
- 630 W. Germantown Pike, Suite 215
- City
- Plymouth Meeting
- State / country code
- PA
- Postal code
- 19462
Prior-sale reporting
- Nothing to report for the preceding three months
- N
Notice signature
- Notice date
- 08/07/2026
- Signed
- /s/ Jonathan Shulkin
Company context
Harmony Biosciences is a pharmaceutical company dedicated to developing and commercializing innovative therapies for patients with rare neurological diseases who have unmet medical needs. Driven by novel science, visionary thinking, and a commitment to those who feel overlooked, Harmony Biosciences is nurturing a future full of therapeutic possibilities that may enable patients with rare neurological diseases to truly thrive. Established by Paragon Biosciences, LLC, in 2017 and headquartered in Plymouth Meeting, Pa., we believe that when empathy and innovation meet, a better future can begin; a vision evident in the therapeutic innovations we advance, the culture we cultivate, and the community programs we foster. For more information, please visit www.harmonybiosciences.com.
Current securities
Recent company filings
- Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureOct 13, 2026
- 10-Q filingAug 4, 2026
- Results of Operations and Financial Condition · Regulation FD DisclosureAug 4, 2026
- SCHEDULE 13G - filed by VANGUARD PORTFOLIO MANAGEMENT LLC regarding Harmony Biosciences Holdings, Inc.Jul 31, 2026
- Results of Operations and Financial Condition · Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements · Regulation FD DisclosureJul 16, 2026